Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FLT PET/CT for Predicting Chemotherapy Response in Locally Advanced Breast Cancer
NCT00572728Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2008
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorothymidine F-18 in breast cancer, sponsored by National Cancer Institute. Primary endpoint: Percentage Change in Standardized Uptake Value at 60 Minutes (SUV60) Between Baseline and Early-Therapy Correlated with Pathologic Complete Response. Started Dec 2008; status: completed.
02
Drugs
fluorothymidine F-18
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00572728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00572728.